Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

Clinical trial NCT05207709 · TERMINATED

Trial details

NCT number: NCT05207709
Sponsor: SOLTI Breast Cancer Research Group
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2022-03-28
Primary completion: 2026-03-26
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.